RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 ANNEXA-A
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 21
SP 9
OP 9
DO 10.1177/1559897715599366
UL http://mdc.sagepub.com/content/15/21/9.1.abstract
AB In part 2 of the phase 3 ANNEXA-A trial, older subjects receiving a steady dose of apixaban were randomized to receive a bolus plus an infusion of andexanet alfa or placebo in a 3:1 ratio. Andexanet significantly reduced anti-fXa activity, decreased free apixaban, and normalized anticoagulation parameters. It was well tolerated in all study participants.